Pfizer is making progress not only against Covid-19, but also against cancer. Arvinas and the US pharmaceutical company announced this Thursday a global collaboration to develop and commercialize ARV-471, an investigational oral Protac estrogen receptor protein degrader. Pfizer will pay more than $ 600 million to advance investigations.
Under the terms of the agreement, Pfizer will pay Arvinas $ 650 million in advance. Separately, the multinational will make another investment of 350 million dollars. The companies will share equally in development costs, marketing expenses and profits worldwide.
The estrogen receptor is a known disease factor in most breast cancers. ARV-471 is currently in a phase II dose expansion clinical trial for the treatment of patients with locally advanced or metastatic breast cancer.
Pfizer will make another investment, later, of more than 300 million dollars
Arvinas and Pfizer will jointly develop ARV-471 through a clinical program designed to position ARV-471 as an endocrine spinal therapy of choice across the entire breast cancer treatment paradigm, from adjuvant setting to metastatic disease. late line.
The closing of the deal is subject to completion of the review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the United States, in addition to other customary closing conditions. Goldman Sachs acts as the exclusive financial advisor to Arvinas.
“This collaboration has the potential to be transformative, combining our leadership in specific protein degradation with Pfizer’s global capabilities and deep expertise in breast cancer,” explains John Houston, CEO of Arvinas.
–
